Gastroenterology Research and Practice / 2017 / Article / Tab 2

Research Article

Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors

Table 2

Subgroup comparisons of SSTR2A, IGF-1R, and p-mTOR QSs.

SSTR2A QSIGF-1R QSp-mTOR QS
Median (IQR)Median (IQR)Median (IQR)

GenderF4.6 (1.0–6.4)0.5930.3 (0.0–3.2)0.4963.0 (0.8–4.9)0.180
M2.7 (1.1–7.2)0.3 (0.0–1.8)3.6 (1.1–8.5)
SyndromeYes2.4 (0.0–6.0)0.1160.5 (0.0–3.2)0.7071.0 (0.0–4.9)0.033
No4.3 (1.3–7.2)0.3 (0.0–2.3)3.5 (1.9–6.7)
PrimaryPancreas4.8 (1.0–6.5)0.8010.5 (0.0–2.9)0.2762.0 (0.8–3.4)<0.001
GI3.0 (1.1–6.4)0.2 (0.0–1.8)6.7 (3.1–8.8)
StageI-II6.4 (3.0–8.0)<0.0011.1 (0.1–3.3)0.0022.0 (0.3–3.6)<0.001
IIIB-IV2.1 (0.6–4.2)0.0 (0.0–0.7)5.0 (2.7–8.5)
GradingG14.3 (1.0–7.6)0.1580.9 (0.0–3.2)0.0052.9 (0.6–5.6)0.143
G22.8 (0.8–5.6)0.0 (0.0–0.4)4.0 (2.0–6.1)

SSTR2A: somatostatin receptor 2A; IGF-1R: insulin-like growth factor-1 receptor; p-mTOR: phosphorylated mammalian target of rapamycin; QS: quantitative score; IQR: interquartile range; GI: gastrointestinal.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.